National Institute of Health and Medical Research

Université Nice Sophia Antipolis

Centre National De La Recherche Scientifique

Institut De Recherche Pour Le Developpement

Centre Hospitalier Universitaire De Nice

Guillaume Robert

Patrick Auberger

Rachid Benhida

Eric Deharo

Geneviève Bourdy

Valérie Jullian

Vincent Malnuit

Mohsine Driowya

Alexandre Puissant

Thomas Cluzeau

Valerie Jullian

Genevieve Bourdy

Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.

Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same

The invention relates to Simalikalactone E (SkE) to be used for preventing and/or treating cancers.

Use of simalikalactone E as an anticancer agent

A method of treatment of a human patient suffering from myeloid neoplasias, includes administrating a therapeutically effective amount of 5-aminoimidazole-4-carboxamide (acadesine), acadesine precursors or acadesine derivatives.

Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide

Growing community of inventors

Nice, France

Guillaume Robert